With Eli Lilly's diabetes and obesity products Mounjaro and Zepbound booming in popularity, the drugmaker finds itself in a ...
Eli Lilly and Co. approved a program to buy back as much as $15 billion of its own shares amid rapid growth fueled in part by ...
Including the acquisition and expansion of the manufacturing facility, Eli Lilly will be investing $4bn in the site. After ...
The Zacks Daily presents the best research output of our analyst team. Today's Daily features new research reports on 16 ...
Eli Lilly and Company LLY announced that its board of directors approved a new $15 billion share buyback plan. The earlier $5 ...
Zepbound outperformed Wegovy for weight loss in a new clinical trial funded by Eli Lilly & Co., Zepbound's maker.
One particular healthcare stock has shown its ability to soar on good news -- and it's had plenty of it. This year the ...
Weight-loss drugs could be a boon for insurers, but it is too soon to tell whether the industry will be transformed, the head ...
Roche is developing the tests in partnership with Indianapolis-based Eli Lilly and Co. Earlier this year, the U.S. Food and ...
Ollie's Bargain Outlet and United Natural Foods both topped earnings estimates, lifting the retail stocks early Tuesday.
Ollie's Bargain Outlet and United Natural Foods both topped earnings estimates, lifting the retail stocks early Tuesday.
Statement of transactions by members of senior management and their related parties in shares, issued by MT Højgaard Holding A/S and related securities, cf. article 19 of the EU Regulation 596/2014.